XLO Stock Overview
A clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Xilio Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.89 |
| 52 Week High | US$1.93 |
| 52 Week Low | US$0.49 |
| Beta | -0.20 |
| 11 Month Change | -6.11% |
| 3 Month Change | -2.43% |
| 1 Year Change | -24.73% |
| 33 Year Change | -95.52% |
| 5 Year Change | n/a |
| Change since IPO | -94.43% |
Recent News & Updates
Shareholder Returns
| XLO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.2% | 2.5% | 2.2% |
| 1Y | -24.7% | 16.1% | 31.6% |
Return vs Industry: XLO underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: XLO underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| XLO volatility | |
|---|---|
| XLO Average Weekly Movement | 18.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XLO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XLO's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 56 | Rene Russo | xiliotx.com |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies.
Xilio Therapeutics, Inc. Fundamentals Summary
| XLO fundamental statistics | |
|---|---|
| Market cap | US$39.21m |
| Earnings (TTM) | -US$62.80m |
| Revenue (TTM) | US$4.62m |
8.5x
P/S Ratio-0.6x
P/E RatioIs XLO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XLO income statement (TTM) | |
|---|---|
| Revenue | US$4.62m |
| Cost of Revenue | US$0 |
| Gross Profit | US$4.62m |
| Other Expenses | US$67.42m |
| Earnings | -US$62.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,359.37% |
| Debt/Equity Ratio | 0% |
How did XLO perform over the long term?
See historical performance and comparison